评估丙二酰磷脂补充肝和阻塞性黄疸患者的疗效,安全性和分子机制
临床研究评估丙二昔丁林的疗效,安全性和分子机制在肝后和肝后肝后患者
Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Tanta、埃及、31111
- Faculty of Pharmacy, Tanta University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients age 18-70 years old.
- Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.
Exclusion Criteria:
-
Pregnancy.
- Nursing mothers.
- Patients with increased indirect bilirubin level.
- Patients who have Gilbert syndrome or Crigler Najjar syndrome.
- History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
- Recent hemorrhage.
- Patients who have risk factors potentially complicated by hemorrhage.
- Taking anticoagulants or antiplatelet therapy.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:Control arm
20 patients who will receive supportive treatment for jaundice only, for 3 months. |
|
|
实验性的:PTX arm
20 patients who will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months. |
Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The change from baseline in (Total and Direct bilirubin)
大体时间:The participants will be assessed before initiation of the study (baseline), and at the end of the study up to12 weeks.
|
measurement of(Total and Direct bilirubin) in mg/dL from blood samples will be assessed for all participants. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to12 weeks.
|
|
The change from baseline in aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP)
大体时间:The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
|
measurement of aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) all in U/L from blood samples will be assessed for all participants. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse events and toxicity
大体时间:up to 12 weeks
|
Adverse events and toxicity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5 |
up to 12 weeks
|
|
Change in total antioxidant capacity (TAC) level,
大体时间:The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of total antioxidant capacity (TAC) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
|
Change in tumor necrosis factor alpha (TNF-α)
大体时间:The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of tumor necrosis factor alpha (TNF-α) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
|
Change in liver-fatty acid binding protein (L-FABP)
大体时间:The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of liver-fatty acid binding protein (L-FABP) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TP/RE1/24Ph-1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be publicly shared to ensure participant privacy and confidentiality, as explicit consent for secondary data sharing was not obtained during the study enrollment.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.